C4 Therapeutics, Inc. (CCCC) stock
Close on Nov 11, 2026Market cap $355.54MP/E –Yield –
C4 Therapeutics, Inc. grew revenue 7.2% to $32.28M over the twelve months to Sep 30, 2026. Free cash flow was -$79.74M. At the latest close the market valued the company at $355.54M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $355.54M
- P/E ratio
- –
- Price to sales
- 11.02
- Price to book
- 1.56
- Dividend yield
- –
- Free cash flow yield
- -22.43%
Fundamentals
- Revenue
- $32.28M
- Net income
- -$91.09M
- EPS, diluted
- -$0.71
- Free cash flow
- -$79.74M
- Book value per share
- $1.68
- Diluted shares
- 136M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $3.00
- Open
- $3.04
- Day's range
- $2.86 – $3.06
- Volume
- 2,133,047
- Average volume (20 days)
- 2,967,140
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 2.52
- 52-week range
- $1.69 – $5.17
- RSI (14 days)
- 42.5
- Volatility (1 year)
- 80.9%
- Relative volume
- 0.82×
- WACC
- 17.4%
On 3 of our idea lists: More cash than they're worth, Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CCCC | S&P 500 | Difference | CCCC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.5% | -2.4% | −6.1 pts | ||
| 3 months | -25.3% | -1.2% | −24.2 pts | ||
| Year to date | +51.3% | +12.3% | +39.0 pts | ||
| 1 year | +16.5% | +12.4% | +4.1 pts | ||
| 3 years | +68.0% | +78.8% | −10.8 pts | +18.9% | +21.4% |
| 5 years | -93.3% | +75.2% | −168.4 pts | -41.7% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases C4 Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Update
About C4 Therapeutics
Biological Products, (No Diagnostic Substances)
This clinical-stage biopharmaceutical company focuses on developing targeted protein degradation therapies to address unmet medical needs. Utilizing its proprietary TORPEDO platform, the company creates orally bioavailable small-molecule medicines designed to destroy disease-causing proteins via natural cellular processes. Its clinical pipeline features cemsidomide, a molecular glue degrader being evaluated for multiple myeloma, and CFT8919, an allosteric degrader targeting non-small cell lung cancer with specific genetic mutations. The company also advances early-stage discovery programs directed at inflammation, neuroinflammation, and neurodegenerative conditions, serving patient populations facing severe oncologic and neurological disorders.
Company profile, executives and historyC4 Therapeutics stock: common questions
What is C4 Therapeutics's stock price?
CCCC closed at $2.89 on Nov 11, 2026, down 3.67% on the day. Over the past 52 weeks it traded between $1.69 and $5.17.
What is C4 Therapeutics's market cap?
C4 Therapeutics was worth $355.54M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CCCC's P/E ratio?
C4 Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.71), so it has no meaningful P/E ratio.
How much revenue does C4 Therapeutics make?
C4 Therapeutics reported revenue of $32.28M for the twelve months to Sep 30, 2026, up 7.2% from a year earlier.
Does C4 Therapeutics pay a dividend?
No. C4 Therapeutics has not paid a cash dividend over the last twelve months.
When does C4 Therapeutics report earnings next?
C4 Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CCCC stock performed over the past year?
Including dividends, CCCC returned +16.5% over the past year, against +12.4% for the S&P 500.
How many CCCC shares are sold short?
47M shares were sold short at the latest FINRA report, 38.94% of the float, or 15.1 days of average trading volume.
Who are C4 Therapeutics's competitors?
Companies most similar to C4 Therapeutics by business, industry and size include STRO, KYMR, GLUE, VYGR, CRSP.
See a number that looks wrong?